Tirofiban
Platelet Aggregation Inhibitors Excl. Heparin
Sold as AGGRASTAT
- Drug class
- Platelet Aggregation Inhibitors Excl. Heparin
- Availability
- Prescription only
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 4
Overview
Plain-language summary, compiled from the cited regulatory records
Tirofiban is a medication classified as a platelet aggregation inhibitor [1]. It functions by inhibiting the aggregation of platelets, which are blood components that play a role in clot formation [1].
Tirofiban hydrochloride injection is approved to reduce the rate of thrombotic cardiovascular events in patients diagnosed with non-ST elevation acute coronary syndrome (NSTE-ACS) [1]. These events include a composite endpoint of death, myocardial infarction, or refractory ischemia requiring a repeat cardiac procedure [1].
This medication is available under various brand names [1]. In the past 12 months, there have been [null] adverse event reports submitted for tirofiban [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 1, 2026 |
| US United States | FDA | 1 | November 9, 2024 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
2 products
Uses
Tirofiban is indicated for the prevention of early myocardial infarction in adult patients presenting with acute coronary syndromes without ST elevation (NSTE- ACS) with the last episode of chest pain occurring within 12 hours and with ECG changes and/or elevated cardiac enzymes.
Patients most likely to benefit from tirofiban treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous coronary intervention (PCI).
1). Tirofiban is intended for use with acetylsalicylic acid (ASA) and unfractionated heparin.
How to take
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Tirofiban hydrochloride injection is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
( 1 )
How to take
CACanada· Health Canada
1 product
Uses
AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 3 WARNINGS AND PRECAUTIONS .................................................................................
4 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS .................................................................................................
11 DOSAGE AND ADMINISTRATION ............................................................................. 12 OVERDOSAGE ................................................................................................................
17 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 17 STORAGE AND STABILITY ......................................................................................... 19 SPECIAL HANDLING INSTRUCTIONS .......................................................................
Drug interactions
Known interactions involving Tirofiban. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL514630082 · revised September 1, 2025
- [2]FDA DailyMed · 13ea7fb8-4b01-42… · revised November 9, 2024 [PDF]
- [3]Health Canada (DPD) · 02240706 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.